10 | Cancer Commissioning Strategy Framework Cancer Commissioning Strategy Framework | 11 Strengthening Integrated Delivery • Develop MDTs within PCNs with community and secondary care support to reduce waiting lists. • Integrate health and social care teams for joint triage and create networks for MDTs to support complex needs across GP practices. Population Health Management • Integrate cancer data with wider health determinants. • Embed health inequality indicators in performance metrics for equitable cancer care. Personalised Care • Enhance personalised care planning for cancer patients. • Develop digital support for proactive home care. Collaborative Efforts • Strengthen engagement with VCSE sectors. • Make social prescribing visible, accessible, and available. Addressing Health Inequalities • Implement recommendations from the NCL Inclusion Health Needs Assessment to serve underserved populations. • Expand the Health Inequalities Fund to scale interventions reducing cancer care disparities. Prevention and Early Intervention • Focus on prevention, early intervention, and proactive care to improve cancer outcomes. • Raise awareness and educate on cancer prevention and early detection with community organisations and health campaigns. North Central London Population Health and Integrated Care Strategy (2023) Faster Diagnosis and Operational Performance: • Faster Diagnosis Priority Pathways – Skin, Gynaecology, Urology, Breast. Early Diagnosis: • Targeted Lung Health Checks (TLHC). • Multi-Cancer Blood Test Programme (formerly Galleri Interim Implementation pilot). • Faecal Immunochemical Testing (FIT). • Liver Surveillance. • Liver Pilots. • Community Pharmacy Pilots. • Pancreatic Cancer. Local Early Diagnosis Initiatives: • Screening. • Timely Presentation. • Primary Care Pathways. • Innovation. • Health Inequalities. Treatment and Care: • Treatment Variation. • Living With and Beyond Cancer. • Experience of Care. Cross-Cutting: • Workforce. • People and Community. • Engagement. 2024/25: Cancer Alliance Planning Pack (2024) North Central London Workforce Strategy (2023) Ensure Sufficient Workforce Capacity and Optimise Allocation • Collaborate with educational providers for adequate workforce capacity. • Offer apprenticeships for entry into health and social care. • Provide local job opportunities with flexible employment models. Develop the Right Skills and Expertise • Support career development in cancer care. • Develop advanced clinical practice roles alongside generalist roles. • Emphasise digital, data-focused roles and technology innovations. Enhance Quality and Safety and Improve Patient Experience and Outcomes • Use technological advancements to improve cancer care. • Boost productivity with digitally enhanced pathways. • Move towards an integrated workforce model for holistic cancer care. Promote Collaboration • Foster inclusion and meaningful contribution in the cancer care workforce. • Encourage collaboration among healthcare providers across sectors. North Central London Primary Care Cancer Strategy (2022-25) All Cancers. Increase Screening Uptake: Engage PCNs with low screening uptake. Utilise community engagement and social media to raise awareness. Embed cancer awareness in Making Every Contact Count (MECC) training. Specific Cancer Types: • Bowel Cancer: Support the bowel screening age extension to 50 years. Integrate Lynch Syndrome pathway into bowel cancer screening. Develop targeted communications to improve awareness and participation. • Breast Cancer: Implement call and recall systems to improve screening uptake. Develop a network of champions to promote breast screening. Transition to electronic results sharing with GP practices. • Cervical Cancer: Support the roll-out of HPV self-sampling. Increase HPV vaccine uptake among school-aged children. Extend screening recall frequency. • Lung Cancer: Expand Targeted Lung Health Checks to cover the full population. Increase participation, especially in deprived areas. Specific Initiatives • Community Engagement: Collaborate with local authorities, VCS organisations, and community groups to disseminate information. Design activities for delivery through community pharmacies. • Targeted Campaigns: Utilise resources to target specific demographics (e.g., BAME, people with learning disabilities, severe mental illness). • Training and Education: Update MECC and other education packages to address population needs. Promote MECC training across the sector. North Central London Cancer Alliance Acute Diagnostics and Treatment Delivery Group (ADTDG) (2024) 1. FIT (Faecal Immunochemical Testing). Evaluate pathway impact and decide on future delivery in primary or secondary care. 2. Treatment Variation. Focus on existing pathways (Lung, Breast, Prostate, Bowel) and expand as needed. Add new pathways, including oesophago-gastric cancer and SACT service evaluations. 3. Breast Pain. Implement sustainable breast pain pathways across all providers by Q4 24/25. 4. Skin 2ww Teledermatology. Roll out teledermatology services across all USC skin pathway providers by June 2024. Ensure services are commissioned as BAU by March 2025. 5. Lynch Syndrome. Provide oversight and support for Lynch Syndrome services, including a surveillance hub pilot at UCLH. 6. Non-Specific Symptoms (NSS). Support full commissioning of NSS pathways by Q4 24/25. 7. Colon Capsule Endoscopy (CCE). Evaluate CCE effectiveness and support providers wishing to continue the service. 8. Breast Outcomes. Conclude the project by Q4, with oversight moving to the Breast ERG. 9. Liver Surveillance. Establish a baseline and implement quality improvements across providers. Implement national minimum standards for hepatocellular carcinoma surveillance pathways. 10. Recording BPTP Milestones. Continue collecting BPTP data to monitor colorectal and prostate diagnostics waiting times. 11. COSD/Staging Completeness. Support providers in meeting national data completeness standards and facilitate shared learning. 12. MDT Optimisation. Develop and implement care standards for MDTs across the sector. 13. Admin and Clerical Workforce. Conduct biannual audits of the cancer MDT Coordinator workforce. 14. Patient Engagement and Involvement and Experience of Care. Seek patient representation in each ERG and involve patients in pathway changes. 15. Clinical Networks. Maintain existing ERGs and fund Network Directors. 16. Research. Support existing research projects within the ADT programme. 17. Low Volume High Risk Pathways. Maintain oversight of low volume cancer pathways and engage with Network and medical directors to address issues and opportunities. Cancer Patient Experience Survey. 2023 Results.North Central London Cancer Alliance. Published July 2024 • Questions above expected range - Q58. Cancer research opportunities were discussed with patient. • Questions below expected range - Q6. Q8. Q12. Q16. Q18. Q20. Q28. Q39. Q44. Q50. Q51. Q53. North Central London Cancer Prevention, Awareness and Screening (2023-28) Documents awaiting publication. GP Direct Access Diagnostics for people not meeting NG12, Workforce Strategy, Radiotherapy Workforce and Equipment Strategy NCL CANCER ALLIANCE STRATEGIC AIMS 2023-28 SA1. Improve survival, focusing on early diagnosis, and prevention SA2. Deliver the highest standards of patient experience and improve quality of life SA3. Support the operational delivery of high performing, innovative and sustainable cancer diagnostic and treatment services SA4. Reduce health inequalities across our whole population SA5. Ensure we have the right workforce in place and that we deliver the highest standards of staff experience SA6. Foster innovative approaches and practice in cancer diagnostics, care and treatment Key Theme 1 • Reducing variation and Health inequalities across NCL. Key Theme 2 • Basing cancer care practice on data and alalytics. Key Theme 3 • Optimizing cancer screening uptake (concentrating on breast and cervical). Key Theme 4 • Enhancing a culture of learning and development. Key Theme 5 • Creating a community of practice. Key Theme 6 • Contribute to the operational performance of the overall cancer pathway.
RkJQdWJsaXNoZXIy NTI5NzM=